27812347|t|T2-Imaging Changes in the Nigrosome-1 Relate to Clinical Measures of Parkinson's Disease
27812347|a|The nigrosome-1 region of the substantia nigra (SN) undergoes the greatest and earliest dopaminergic neuron loss in Parkinson's disease (PD). As T2-weighted magnetic resonance imaging (MRI) scans are often collected with routine clinical MRI protocols, this investigation aims to determine whether T2-imaging changes in the nigrosome-1 are related to clinical measures of PD and to assess their potential as a more clinically accessible biomarker for PD. Voxel intensity ratios were calculated for T2-weighted MRI scans from 47 subjects from the Parkinson's Progression Markers Initiative database. Three approaches were used to delineate the SN and nigrosome-1: (1) manual segmentation, (2) automated segmentation, and (3) area voxel -based morphometry. Voxel intensity ratios were calculated from voxel intensity values taken from the nigrosome-1 and two areas of the remaining SN. Linear regression analyses were conducted relating voxel intensity ratios with the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) sub-scores for each subject. For manual segmentation, linear regression tests consistently identified the voxel intensity ratio derived from the dorsolateral SN and nigrosome-1 (IR2) as predictive of nBehav (p = 0.0377) and nExp (p = 0.03856). For automated segmentation, linear regression tests identified IR2 as predictive of Subscore IA (nBehav) (p = 0.01134), Subscore IB (nExp) (p = 0.00336), Score II (mExp) (p = 0.02125), and Score III (mSign) (p = 0.008139). For the voxel -based morphometric approach, univariate simple linear regression analysis identified IR2 as yielding significant results for nBehav (p = 0.003102), mExp (p = 0.0172), and mSign (p = 0.00393). Neuroimaging biomarkers may be used as a proxy of changes in the nigrosome-1, measured by MDS-UPDRS scores as an indicator of the severity of PD. The voxel intensity ratio derived from the dorsolateral SN and nigrosome-1 was consistently predictive of non-motor complex behaviors in all three analyses and predictive of non-motor experiences of daily living, motor experiences of daily living, and motor signs of PD in two of the three analyses. These results suggest that T2 changes in the nigrosome-1 may relate to certain clinical measures of PD. T2 changes in the nigrosome-1 may be considered when developing a more accessible clinical diagnostic tool for patients with suspected PD.
27812347	0	10	T2-Imaging	T058	UMLS:C0412676
27812347	26	37	Nigrosome-1	T017	UMLS:C1512035
27812347	69	88	Parkinson's Disease	T038	UMLS:C0030567
27812347	93	104	nigrosome-1	T017	UMLS:C1512035
27812347	119	135	substantia nigra	T017	UMLS:C0038590
27812347	137	139	SN	T017	UMLS:C0038590
27812347	177	201	dopaminergic neuron loss	T033	UMLS:C3550005
27812347	205	224	Parkinson's disease	T038	UMLS:C0030567
27812347	226	228	PD	T038	UMLS:C0030567
27812347	234	284	T2-weighted magnetic resonance imaging (MRI) scans	T058	UMLS:C0412676
27812347	327	330	MRI	T058	UMLS:C0024485
27812347	347	360	investigation	T058	UMLS:C0220825
27812347	387	397	T2-imaging	T058	UMLS:C0412676
27812347	413	424	nigrosome-1	T017	UMLS:C1512035
27812347	461	463	PD	T038	UMLS:C0030567
27812347	526	535	biomarker	T201	UMLS:C0005516
27812347	540	542	PD	T038	UMLS:C0030567
27812347	587	608	T2-weighted MRI scans	T058	UMLS:C0412676
27812347	635	646	Parkinson's	T038	UMLS:C0030567
27812347	678	686	database	T170	UMLS:C0242356
27812347	732	734	SN	T017	UMLS:C0038590
27812347	739	750	nigrosome-1	T017	UMLS:C1512035
27812347	763	775	segmentation	T058	UMLS:C0200768
27812347	791	803	segmentation	T058	UMLS:C0200768
27812347	831	842	morphometry	T058	UMLS:C0200760
27812347	926	937	nigrosome-1	T017	UMLS:C1512035
27812347	969	971	SN	T017	UMLS:C0038590
27812347	1056	1122	Movement Disorder Society-Unified Parkinson's Disease Rating Scale	T170	UMLS:C3639714
27812347	1124	1133	MDS-UPDRS	T170	UMLS:C3639714
27812347	1175	1187	segmentation	T058	UMLS:C0200768
27812347	1280	1292	dorsolateral	T082	UMLS:C2983598
27812347	1293	1295	SN	T017	UMLS:C0038590
27812347	1300	1311	nigrosome-1	T017	UMLS:C1512035
27812347	1335	1341	nBehav	T058	UMLS:C1160858
27812347	1359	1363	nExp	T033	UMLS:C0243095
27812347	1393	1405	segmentation	T058	UMLS:C0200768
27812347	1476	1482	nBehav	T058	UMLS:C1160858
27812347	1512	1516	nExp	T033	UMLS:C0243095
27812347	1543	1547	mExp	T038	UMLS:C0026612
27812347	1579	1584	mSign	T170	UMLS:C3639714
27812347	1623	1644	morphometric approach	T058	UMLS:C0200760
27812347	1742	1748	nBehav	T058	UMLS:C1160858
27812347	1765	1769	mExp	T038	UMLS:C0026612
27812347	1788	1793	mSign	T033	UMLS:C0037088
27812347	1809	1821	Neuroimaging	T058	UMLS:C0679575
27812347	1822	1832	biomarkers	T201	UMLS:C0005516
27812347	1874	1885	nigrosome-1	T017	UMLS:C1512035
27812347	1899	1908	MDS-UPDRS	T170	UMLS:C3639714
27812347	1951	1953	PD	T038	UMLS:C0030567
27812347	1998	2010	dorsolateral	T082	UMLS:C2983598
27812347	2011	2013	SN	T017	UMLS:C0038590
27812347	2018	2029	nigrosome-1	T017	UMLS:C1512035
27812347	2071	2088	complex behaviors	T033	UMLS:C0474411
27812347	2207	2218	motor signs	T033	UMLS:C0037088
27812347	2222	2224	PD	T038	UMLS:C0030567
27812347	2300	2311	nigrosome-1	T017	UMLS:C1512035
27812347	2355	2357	PD	T038	UMLS:C0030567
27812347	2377	2388	nigrosome-1	T017	UMLS:C1512035
27812347	2450	2465	diagnostic tool	T058	UMLS:C0430022
27812347	2494	2496	PD	T038	UMLS:C0030567